Replies to post #19079 on Biotech Values

[drbio45]

the case for staar surgical

the company is near breakeven

they had a problem with compliance issues causing them to have problems with the fda. As the 8k attests the compliance issues have been resolved

This will allow the ICL lense which has been in limbo for 2 years to finally be approved. This product by itself can easily do 100 million dollars with gross margins probably in the 70 percent range most of which will flow to he bottom line because the base business is in place to handle the sales.

AMO came to the market with a product first but it is clearly inferior. In fact an analyst from Piper who follows AMO wrote in his report that the lens from AMO isn't selling because the doctors were waiting for Staar's lens to be approved because of its superiority. There is no one else with a product like staar's which will give them the market to themselves for a few years